Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites.


Journal

United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 28 3 2020
medline: 29 6 2021
entrez: 28 3 2020
Statut: ppublish

Résumé

Nosocomial infections are a particular threat for patients with liver cirrhosis. It is not uncommon that individuals develop even several consecutive infections during a single hospital stay. We aimed to investigate the impact and characteristics of multiple, consecutive nosocomial infections. A total of 514 consecutive patients with liver cirrhosis and ascites were included and followed up for 28 days for nosocomial infection, death or liver transplantation (LTx). Laboratory values were assessed at the time of hospitalization as well as at the onset of each new infectious episode. 58% ( In patients with decompensated liver cirrhosis LTx-free survival significantly decreases with every consecutive infectious episode. Development of prevention strategies is urgently required.

Sections du résumé

BACKGROUND
Nosocomial infections are a particular threat for patients with liver cirrhosis. It is not uncommon that individuals develop even several consecutive infections during a single hospital stay. We aimed to investigate the impact and characteristics of multiple, consecutive nosocomial infections.
METHODS
A total of 514 consecutive patients with liver cirrhosis and ascites were included and followed up for 28 days for nosocomial infection, death or liver transplantation (LTx). Laboratory values were assessed at the time of hospitalization as well as at the onset of each new infectious episode.
RESULTS
58% (
CONCLUSION
In patients with decompensated liver cirrhosis LTx-free survival significantly decreases with every consecutive infectious episode. Development of prevention strategies is urgently required.

Identifiants

pubmed: 32213043
doi: 10.1177/2050640620913732
pmc: PMC7268939
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

567-576

Références

Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
Nat Immunol. 2013 Oct;14(10):996-1006
pubmed: 24048121
Hepatology. 2015 Jul;62(1):243-52
pubmed: 25877702
J Gastroenterol Hepatol. 2001 Jun;16(6):607-12
pubmed: 11422611
J Hepatol. 2019 Mar;70(3):398-411
pubmed: 30391380
Cell. 2006 Mar 10;124(5):915-27
pubmed: 16530040
Liver Int. 2015 Feb;35(2):391-400
pubmed: 25039438
Am J Transplant. 2011 Jul;11(7):1435-43
pubmed: 21718440
Am J Gastroenterol. 2017 Apr;112(4):588-596
pubmed: 28220780
Gastroenterology. 2010 Oct;139(4):1246-56, 1256.e1-5
pubmed: 20558165
Semin Liver Dis. 2016 May;36(2):109-16
pubmed: 27172351
Gut. 2015 Apr;64(4):531-7
pubmed: 25631669
J Hepatol. 2014 Jul;61(1):51-8
pubmed: 24681345
Hepatology. 2002 Jan;35(1):140-8
pubmed: 11786970
World J Hepatol. 2016 Feb 28;8(6):307-21
pubmed: 26962397
Eur J Clin Invest. 2017 Jan;47(1):44-52
pubmed: 27861767
N Engl J Med. 2010 Aug 12;363(7):689-91
pubmed: 20818861
Hepatology. 2008 Feb;47(2):729-36
pubmed: 18167066
Am J Gastroenterol. 2018 Apr;113(4):556-563
pubmed: 29257141
Clin Infect Dis. 2011 May;52 Suppl 6:S433-6
pubmed: 21498836
Sci Rep. 2017 Apr 06;7:46025
pubmed: 28382951
Hepatology. 2012 Dec;56(6):2328-35
pubmed: 22806618
J Hepatol. 2009 Sep;51(3):426-9
pubmed: 19615779
Gastroenterology. 2019 Apr;156(5):1368-1380.e10
pubmed: 30552895
Gut. 2018 Oct;67(10):1870-1880
pubmed: 28847867
J Hepatol. 2012 Dec;57(6):1336-48
pubmed: 22750750
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
Hepatology. 2006 Feb;43(2 Suppl 1):S54-62
pubmed: 16447271
Stat Med. 2013 Aug 15;32(18):3077-88
pubmed: 23436643
Clin Infect Dis. 2011 May;52 Suppl 6:S452-6
pubmed: 21498838
J Infect. 2004 Oct;49(3):248-52
pubmed: 15337343
Clin Microbiol Infect. 2018 May;24(5):546.e1-546.e8
pubmed: 28818628
Am J Gastroenterol. 2014 Sep;109(9):1436-42
pubmed: 25091061

Auteurs

Marie Schultalbers (M)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Tammo L Tergast (TL)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Nicolas Simon (N)

Centre for Information Management (ZIMt), Hannover Medical School, Hannover, Germany.

Abdul-Rahman Kabbani (AR)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Markus Kimmann (M)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Christoph Höner Zu Siederdissen (CH)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Svetlana Gerbel (S)

Centre for Information Management (ZIMt), Hannover Medical School, Hannover, Germany.

Michael P Manns (MP)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
German Centre for Infection Research (Deutsches Zentrum für Infektionsforschung DZIF), Hannover, Germany.
Centre for Individualised Infection Medicine (CIIM), c/o CRC Hannover, Hannover, Germany.

Markus Cornberg (M)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
German Centre for Infection Research (Deutsches Zentrum für Infektionsforschung DZIF), Hannover, Germany.
Centre for Individualised Infection Medicine (CIIM), c/o CRC Hannover, Hannover, Germany.

Benjamin Maasoumy (B)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
German Centre for Infection Research (Deutsches Zentrum für Infektionsforschung DZIF), Hannover, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH